BR112022021592A2 - Anticorpo anti-igsf1 e uso do mesmo - Google Patents
Anticorpo anti-igsf1 e uso do mesmoInfo
- Publication number
- BR112022021592A2 BR112022021592A2 BR112022021592A BR112022021592A BR112022021592A2 BR 112022021592 A2 BR112022021592 A2 BR 112022021592A2 BR 112022021592 A BR112022021592 A BR 112022021592A BR 112022021592 A BR112022021592 A BR 112022021592A BR 112022021592 A2 BR112022021592 A2 BR 112022021592A2
- Authority
- BR
- Brazil
- Prior art keywords
- igsf1
- antibody
- present
- overexpressed
- cells
- Prior art date
Links
- 101150009156 IGSF1 gene Proteins 0.000 abstract 7
- 102100022514 Immunoglobulin superfamily member 1 Human genes 0.000 abstract 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000005202 lung cancer Diseases 0.000 abstract 3
- 208000020816 lung neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 210000002865 immune cell Anatomy 0.000 abstract 2
- 230000008595 infiltration Effects 0.000 abstract 2
- 238000001764 infiltration Methods 0.000 abstract 2
- 230000004614 tumor growth Effects 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 238000011577 humanized mouse model Methods 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 210000005087 mononuclear cell Anatomy 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
ANTICORPO ANTI-IGSF1 E USO DO MESMO. A presente invenção se refere a um novo anticorpo que se liga especificamente a IGSF1 e a uma composição farmacêutica para prevenção ou tratamento de câncer, compreendendo o mesmo como ingrediente ativo. Especificamente, a presente invenção fornece um anticorpo que se liga ao terminal C de IGSF1. O anticorpo anti-IGSF1 de acordo com a presente invenção exibiu alta especificidade e alta capacidade de ligação ao IGSF1. O anticorpo anti-IGSF1 de acordo com a presente invenção aumentou a infiltração de células imunes nos esferoides quando os esferoides de células de câncer de pulmão em que IGSF1 é superexpresso foram cocultivados com células mononucleares periféricas humanas. Além disso, o anticorpo anti-IGSF1 de acordo com a presente invenção inibiu o crescimento tumoral em um camundongo humanizado transplantado com células de câncer de pulmão humano em que a IGSF1 é superexpressa e aumentou a expressão de citocinas em tecidos tumorais. Através dos resultados acima, foi confirmado que o anticorpo anti-IGSF1 pode inibir o crescimento tumoral aumentando a infiltração de células imunes em tecidos de câncer de pulmão em que a expressão de IGSF1 é aumentada, e a resposta imune. Portanto, o anticorpo anti-IGSF1 pode ser utilizado como um agente anticâncer para tratar eficazmente o câncer no qual a IGSF1 é superexpressa.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/KR2021/011139 WO2023022271A1 (ko) | 2021-08-20 | 2021-08-20 | 항-igsf1 항체 및 이의 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022021592A2 true BR112022021592A2 (pt) | 2023-03-14 |
Family
ID=85223221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022021592A BR112022021592A2 (pt) | 2021-08-20 | 2021-08-20 | Anticorpo anti-igsf1 e uso do mesmo |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240262906A1 (pt) |
| EP (1) | EP4389766A1 (pt) |
| JP (1) | JP2024535654A (pt) |
| KR (1) | KR20240046103A (pt) |
| CN (1) | CN116635418A (pt) |
| AU (1) | AU2021437023A1 (pt) |
| BR (1) | BR112022021592A2 (pt) |
| CA (1) | CA3177927A1 (pt) |
| WO (1) | WO2023022271A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240057508A (ko) * | 2022-10-24 | 2024-05-03 | 웰마커바이오 주식회사 | 항-ｉｇｓｆ1 항체를 포함하는 암 치료용 약학 조성물 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4942644B2 (ja) * | 2005-02-28 | 2012-05-30 | 株式会社抗体研究所 | 抗ＩｇＳＦ４抗体及びその利用 |
| CN107532199B (zh) | 2014-07-29 | 2021-10-22 | 威马克生物有限公司 | 与间质上皮转化因子抑制剂有关的感受性预测用新型生物标志物及其用途 |
-
2021
- 2021-08-20 US US17/997,019 patent/US20240262906A1/en active Pending
- 2021-08-20 KR KR1020237005825A patent/KR20240046103A/ko active Search and Examination
- 2021-08-20 CN CN202180048750.4A patent/CN116635418A/zh active Pending
- 2021-08-20 AU AU2021437023A patent/AU2021437023A1/en active Pending
- 2021-08-20 WO PCT/KR2021/011139 patent/WO2023022271A1/ko active Application Filing
- 2021-08-20 BR BR112022021592A patent/BR112022021592A2/pt unknown
- 2021-08-20 CA CA3177927A patent/CA3177927A1/en active Pending
- 2021-08-20 JP JP2022574184A patent/JP2024535654A/ja active Pending
- 2021-08-20 EP EP21930594.3A patent/EP4389766A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024535654A (ja) | 2024-10-02 |
| EP4389766A1 (en) | 2024-06-26 |
| CN116635418A (zh) | 2023-08-22 |
| KR20240046103A (ko) | 2024-04-08 |
| AU2021437023A1 (en) | 2023-03-09 |
| CA3177927A1 (en) | 2023-02-20 |
| US20240262906A1 (en) | 2024-08-08 |
| WO2023022271A1 (ko) | 2023-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ding et al. | CD133 facilitates epithelial-mesenchymal transition through interaction with the ERK pathway in pancreatic cancer metastasis | |
| Qin et al. | PI3Kgamma inhibitor attenuates immunosuppressive effect of poly (l‐Glutamic Acid)‐Combretastatin A4 conjugate in metastatic breast cancer | |
| Lee et al. | Reactive oxygen species and PI3K/Akt signaling play key roles in the induction of Nrf2-driven heme oxygenase-1 expression in sulforaphane-treated human mesothelioma MSTO-211H cells | |
| BR112021015098A2 (pt) | Inibidores de enpp1 e métodos de modulação da resposta imune | |
| MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
| Gandullo‐Sánchez et al. | HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies | |
| BR112020016331A8 (pt) | Métodos para tratar câncer com anticorpos anti-pd-1 | |
| Younes et al. | A global, randomized, placebo-controlled, phase 3 study of ibrutinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) in patients with previously untreated non-germinal center B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL) | |
| Zhao et al. | Inhibition of cell proliferation and induction of autophagy by KDM2B/FBXL10 knockdown in gastric cancer cells | |
| Grimaldi et al. | Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway | |
| BR112015022650A8 (pt) | inibidores de quinase induzível por sal macrocíclico. | |
| JOP20220107A1 (ar) | مثبطات egfr تفارغية وطرق استخدامها | |
| BR112021025764A2 (pt) | Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo | |
| BR112022021592A2 (pt) | Anticorpo anti-igsf1 e uso do mesmo | |
| BR112022000382A2 (pt) | Administração de agonista de sting e inibidores de checkpoint | |
| MX2022015739A (es) | Inhibidores alostericos de egfr y metodos de uso de estos. | |
| KR20150054728A (ko) | 세쿠리닌을 유효성분으로 포함하는 암 줄기세포 분화 유도용 조성물 및 이의 용도 | |
| WO2015035410A8 (en) | Cancer therapy | |
| AU2016319111B2 (en) | Azophenols as ERG oncogene inhibitors | |
| BR112016023011A2 (pt) | tratamento de câncer gástrico | |
| BR112022026247A2 (pt) | Método para aumentar a eficácia terapêutica de um agente de imunoterapia, método de tratamento de câncer e método de inibição do crescimento de uma célula de câncer | |
| Thang et al. | Treatment of vemurafenib-resistant SKMEL-28 melanoma cells with paclitaxel | |
| BR112018015448A2 (pt) | conjugado anticorpo-fármaco, composição farmacêutica, métodos para liberar um agente ativo, para tratar uma doença, para inibir progressão de tumor e para inibir, diminuir ou eliminar a capacidade metastática de um tumor, e, kit. | |
| Wang et al. | CSL regulates AKT to mediate androgen independence in prostate cancer progression | |
| BR112022001814A2 (pt) | Métodos de tratamento de câncer multifocal |